ArticleBJC reports2025

Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancer.

Kara M Ruicci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.